Clinical Trials Sponsored by Astellas Pharma Korea, Inc

Total 1239 results

Astellas Pharma Inc
Astellas Pharma US, Inc.

Completed

A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke Patients

Cerebrovascular Accident

Canada, Belgium, United States, Germany, South Africa, Austria
Astellas Pharma Inc
Astellas Pharma US, Inc.

Completed

A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)

Acute Ischemic Stroke

Canada, United States, Germany, Belgium, Austria
Hallym University Medical Center
Astellas Pharma Korea, Inc.; Korean Cancer Study Group

Unknown

Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone (ROAD)

Cancer | Malignancy

Korea, Republic of
Astellas Pharma S.A.S.

Completed

A Study of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf®) to the Once Per Day Form (Advagraf®) (OPALE)

Renal Transplantation

France
Astellas Pharma S.A.S.

Completed

Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients (DAFNE)

Clostridium Difficile Infection

France
Astellas Pharma S.A.S.

Completed

A Multicenter Study in Liver Transplant Patients Converted From Prograf® to Advagraf® During the First Post-transplantation Year (COBALT)

Liver Transplantation

France
Astellas Pharma S.A.S.

Completed

Use of Micafungin (Mycamine®) as Antifungal Prophylaxis in Haematology and Onco-haematology (OLYMPE)

Antifungal Prophylaxis | Haemopathy

France
Astellas Pharma s.r.o.

Completed

A Study of Efficacy and Safety of Qutenza in Patients With Post-operative Peripheral Neuropathic Pain

Post-operative Peripheral Neuropathic Pain

Czech Republic
Astellas Pharma Inc
Astellas Pharma US, Inc.; Advanz Pharma

Completed

Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery

Atrial Fibrillation | Atrial Flutter

Poland, United States, Canada, Argentina, Denmark, India
Seoul National University Hospital
Astellas Pharma Korea, Inc.

Unknown

Beraprost Sodium and Arterial Stiffness in Patients With Type 2 Diabetic Nephropathy

Diabetic Nephropathy

Korea, Republic of
Seoul National University Hospital
Astellas Pharma Korea, Inc.

Completed

Validation of the Korean Version of the Walking Impairment Questionnaire in Patients With Peripheral Arterial Disease

Peripheral Arterial Occlusive Disease

Korea, Republic of
Astellas Pharma Global Development, Inc.

Recruiting

A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas

B-cell Lymphoma

Australia
Astellas Pharma Global Development, Inc.

Recruiting

A Study of ASP1012 in Adults With Solid Tumors

Solid Tumor

United States
Astellas Pharma Global Development, Inc.

Recruiting

A Study of ASP1002 in Adults for Treatment of Solid Tumors

Advanced Solid Tumors

United States
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites

Allergic to House Dust Mites

Germany
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Leukemia, Acute Myeloid (AML)

Japan, United States, Belgium, Canada, France, Germany, Israel, Italy, Korea, Republic of, Poland, Spain, Taiwan, Turkey, United Kingdom
Astellas Pharma Global Development, Inc.

Completed

Incidence and Clinical Burden of Erythropoietin Hyporesponsiveness - a Retrospective Database Analysis

Chronic Kidney Disease

Germany
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of ASP2074 in Adults With Solid Tumors

Advanced Solid Tumors

United States, Japan
Astellas Pharma Global Development, Inc.

Completed

A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause (Daylight)

Vasomotor Symptoms

Poland, Spain, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Norway, Sweden, Turkey, United Kingdom
Astellas Pharma Global Development, Inc.

Terminated

A Study to Assess ASP0598 Otic Solution Following Topical Application in the Ear in Subjects With Chronic Tympanic Membrane Perforation (CTMP)

Chronic Tympanic Membrane Perforation

United States
Astellas Pharma Global Development, Inc.

Terminated

A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB) (Dolphin)

Pharmacokinetics of Mirabegron | Overactive Bladder (OAB)

Korea, Republic of, Russian Federation, Turkey
Astellas Pharma Global Development, Inc.

Completed

Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants

Ovarian Cancer | NSCLC | Solid Tumors | ESCC

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function

Renal Impaired | Gilteritinib | Normal Renal Function | Pharmacokinetics of ASP2215

United States, Bulgaria
Astellas Pharma Global Development, Inc.

Completed

A Study to Learn How [14C]ASP0367 is Processed by the Body in Healthy Men

Healthy Volunteers

United States
Astellas Pharma Global Development, Inc.

Terminated

A Study to Find a Suitable Dose of ASP8731 and Check for Medical Problems at Each Dose in Healthy Adults

Healthy Participants

United States
Astellas Pharma Global Development, Inc.

Completed

Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study

Prostate Cancer | Metastatic Hormone-sensitive Prostate Cancer

United States
Astellas Pharma Global Development, Inc.

Withdrawn

A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder

Opioid Use Disorder
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess Bioequivalence of Fezolinetant Formulations in Healthy Female Participants

Healthy Volunteers

United States
Astellas Pharma Global Development, Inc.

Completed

Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial

Acute Myeloid Leukemia | Advanced Solid Tumors

United States
Astellas Pharma Global Development, Inc.

Completed

To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients (ASTOUND)

Kidney Transplantation

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess the Relative Bioavailability of Gilteritinib Following a Single Dose of Gilteritinib Mini-tablet Oral Suspension and Gilteritinib Mini-tablets Compared to a Single Dose of Gilteritinib Tablet in Healthy Subjects

Healthy Volunteer

United States
Astellas Pharma Global Development, Inc.

Completed

A Study in Healthy Adult Volunteers to Assess the Safety and Pharmacokinetics of an Investigational Imaging Product

Healthy Subjects

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer (ASPIRE-PCa)

Prostate Cancer | Castration-resistant Prostate Cancer | Metastatic Prostate Cancer

Spain, Taiwan, France, Algeria, Argentina, Australia, Austria, Brazil, Canada, Colombia, Egypt, Germany, Indonesia, Israel, Italy, Korea, Republic of, Lebanon, Mexico, Netherlands, New Zealand, Oman, Peru, Philippines, Saudi Arabia, Sin... and more
Astellas Pharma Global Development, Inc.

Terminated

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States, Canada
Astellas Pharma Global Development, Inc.

Completed

Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors

Advanced Solid Tumors | Pharmacokinetics of 14C-labeled Gilteritinib

United States
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Non-Small-Cell Lung Cancer

Japan
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations (SOLAR)

Non-small Cell Lung Cancer (NSCLC)

United States, Australia, Belgium, Canada, Chile, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Portugal, Romania, Russian Federation, Singapore, Spain, Taiwan, Thailand, Ukraine, United Kingdom
Astellas Pharma Global Development, Inc.

Withdrawn

A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors

Solid Tumors | Epidermal Growth Factor Receptor (EGFR) Mutations
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT) (EXERRT)

Coronary Artery Disease (CAD)

United States, Peru, Argentina, Puerto Rico
Astellas Pharma Global Development, Inc.

Terminated

Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis (MAGIC-2)

Candidiasis

Philippines, United States, Canada, Israel, Romania, Greece, Turkey, Brazil, Bulgaria, Colombia, Hungary, Ukraine
Astellas Pharma Global Development, Inc.

Completed

A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K

Healthy Volunteers | Pharmacokinetics of ASP015K | Food Effect

United States
Astellas Pharma Global Development, Inc.

Completed

A Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate

Rheumatoid Arthritis | Pharmacokinetics of ASP2409

United States
Astellas Pharma Global Development, Inc.

Completed

A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP2408 Following Single Intravenous Doses in Healthy Subjects

Healthy Subjects | Pharmacokinetics of ASP2408

United States
Astellas Pharma Global Development, Inc.

Completed

A Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Multiple Dose Subcutaneous Injections in Patients With Rheumatoid Arthritis on Methotrexate

Rheumatoid Arthritis | Pharmacokinetics of ASP2408

United States
Astellas Pharma Global Development, Inc.

Completed

Repeat Dose Tolerance Study of Regadenoson in Healthy Subjects

Healthy Volunteers

United States
Jeong Gu Lee
Astellas Pharma Korea, Inc.

Completed

A Study to Estimate the Efficacy and Safety of Solifenacin in Female With Stress Urinary Incontinence and Urgency Urinary Incontinence

Stress Urinary Incontinence | Urgency Urinary Incontinence

Korea, Republic of
Kim, Seoung-Hoon
Astellas Pharma Korea, Inc.; Linical Korea

Completed

To Evaluate the Efficacy and Safety of ADVAGRAF® After Treatment With a Tacrolimus in New Liver Transplant Recipients

Liver Transplantation
Astellas Pharma Inc

Terminated

A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy (MOUNTAINSIDE)

Primary Mitochondrial Myopathy

United States
Astellas Pharma Inc

Completed

A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Gastric Cancer | Gastro-esophageal Junction (GEJ) Cancer

Japan
Astellas Pharma Inc

Terminated

A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy (DMD)

United States

3

Subscribe